(December 8, 2023, 12:42 PM EST) -- ALEXANDRIA, Va. — A petition by Pfizer Inc. for inter partes review (IPR) of a Moderna TX Inc. patent directed to the messenger RNA technology used in the COVID-19 vaccine is a “transparent” effort to “double-dip,” Moderna says in a Dec. 7 preliminary patent owner response filed with the Patent Trial and Appeal Board....